274 related articles for article (PubMed ID: 32728615)
1. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia.
Zhao X; Yang J; Zhang X; Lu XA; Xiong M; Zhang J; Zhou X; Qi F; He T; Ding Y; Hu X; De Smet F; Lu P; Huang X
Mol Ther Oncolytics; 2020 Sep; 18():272-281. PubMed ID: 32728615
[TBL] [Abstract][Full Text] [Related]
2. Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.
Wu L; Chen J; Cai R; Wang X; Liu Y; Zheng Q; Li L
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345104
[TBL] [Abstract][Full Text] [Related]
3. Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.
Ying Z; He T; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Qi F; Ding Y; Lu XA; Song Y; Zhu J
Mol Ther Oncolytics; 2019 Dec; 15():60-68. PubMed ID: 31650026
[TBL] [Abstract][Full Text] [Related]
4. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
Zhong Q; Zhu YM; Zheng LL; Shen HJ; Ou RM; Liu Z; She YL; Chen R; Li C; Huang J; Yao MD; Zhang Q; Liu S
Acta Haematol; 2018; 140(3):131-140. PubMed ID: 30253384
[TBL] [Abstract][Full Text] [Related]
9. A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
Ying Z; He T; Jin S; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Liu W; Deng L; Ding Y; Hu X; Bu B; Lu X; Song Y; Zhu J
Chin J Cancer Res; 2022 Feb; 34(1):53-62. PubMed ID: 35355931
[TBL] [Abstract][Full Text] [Related]
10. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
11. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
12. Anti-CLL1-based CAR T-cells with 4-1-BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia.
Pei K; Xu H; Wang P; Gan W; Hu Z; Su X; Zhang H; He Y
Cancer Med; 2023 Apr; 12(8):9655-9661. PubMed ID: 37031462
[TBL] [Abstract][Full Text] [Related]
13. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.
Yang C; Lei W; Xie H; Wu G; Wei J; Liang A; Qian W
Onco Targets Ther; 2020; 13():12163-12168. PubMed ID: 33268994
[TBL] [Abstract][Full Text] [Related]
14. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
16. Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL.
Sun M; Xu P; Wang E; Zhou M; Xu T; Wang J; Wang Q; Wang B; Lu K; Wang C; Chen B
Mol Ther Oncolytics; 2021 Dec; 23():96-106. PubMed ID: 34703879
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report.
Htun KT; Gong Q; Ma L; Wang P; Tan Y; Wu G; Chen J
Front Oncol; 2021; 11():699946. PubMed ID: 34513679
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
19. Co-Stimulatory Receptor Signaling in CAR-T Cells.
Honikel MM; Olejniczak SH
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139142
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
